You Zhai

The First Affiliated Hospital

H指数:20

被引数:1,629

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Bioequivalence of two formulations of amitriptyline hydrochloride tablets in healthy Chinese subjects under fasting and fed conditions

盐酸阿米替林片两种制剂在空腹和餐后条件下的健康中国受试者中的生物等效性

BMC Pharmacology & Toxicology

IF2.7

2026-08-210

OAAI

Strategy and clinical benefit of first re-resection for recurrent adult-type diffuse glioma: A retrospective cohort analysis

首次再切除手术策略与临床获益：成人型弥漫性胶质瘤的回顾性队列分析

Med

IF11.8

2025-10-220

PRE

Population Pharmacokinetic Modeling Analysis of ASC10; a Novel Antiviral Agent Targeted COVID-19; in Chinese Healthy Subjects

ASC10在中国健康受试者中的群体药代动力学模型分析；一种针对COVID-19的新型抗病毒药物

drug design development and therapy

IF0

2025-08-260

The development and potent antitumor efficacy of CD44/CD133 dual-targeting IL7Rα-armored CAR-T cells against glioblastoma

CD44/CD133双靶向IL7Rα装甲CAR-T细胞在胶质母细胞瘤中的开发及其强大的抗肿瘤功效

CANCER LETTERS

IF10.1

2025-04-010

PRE

LOCOREGIONAL BI-SPECIFIC CAR-T CELLS TARGETING CD44 AND CD133 IN RECURRENT GLIOBLASTOMA: THE INTERIM RESULTS OF THE FIRST IN-HUMAN CLINICAL TRIAL

NEURO-ONCOLOGY

IF13.4

2024-10-170

PRE

Glycometabolic reprogramming-induced XRCC1 lactylation confers therapeutic resistance in ALDH1A3-overexpressing glioblastoma

CELL METABOLISM

IF30.9

2024-08-014

OAAI

Safety, tolerability and pharmacokinetics of ASC10, a novel oral double prodrug of a broad-spectrum antiviral agent, β-d-N4-hydroxycytidine: results from a randomized, double-blind, placebo-controlled phase 1 study in Chinese healthy subjects

EXPERT OPINION ON INVESTIGATIONAL DRUGS

IF4.1

2024-07-120

Tumour microenvironment programming by an RNA-RNA-binding protein complex creates a druggable vulnerability in IDH-wild-type glioblastoma

NATURE CELL BIOLOGY

IF19.1

2024-06-101

OAAI

Poliovirus receptor-based chimeric antigen receptor T cells combined with NK-92 cells exert potent activity against glioblastoma

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE

IF7.2

2023-11-071

OAAI

RUNX-3-expressing CAR T cells targeting glypican-3 in patients with heavily pretreated advanced hepatocellular carcinoma: a phase I trial

RUNX-3-expressing CAR T细胞靶向glypican-3治疗晚期肝癌患者: I期试验

ECLINICALMEDICINE

IF10

2023-09-0121

OAAI

Diffuse Isocitrate Dehydrogenase-Mutant Gliomas With Histone H3 Alterations Are Distinguished by Unique Clinical Characteristics, Molecular Expression Profile, and Survival Prognosis

NEUROSURGERY

IF3.9

2023-04-182

OAAI

Development of an integrated and comprehensive clinical trial process management system

BMC MEDICAL INFORMATICS AND DECISION MAKING

IF3.8

2023-04-060

OAAI

TREM2 is associated with tumor immunity and implies poor prognosis in glioma

TREM2与肿瘤免疫相关，提示胶质瘤预后不良

FRONTIERS IN IMMUNOLOGY

IF5.9

2023-01-1117

OAAI

Immunological profiles of human oligodendrogliomas define two distinct molecular subtypes

人类少突胶质细胞瘤的免疫学特征定义了两种不同的分子亚型

EBIOMEDICINE

IF10.8

2023-01-019

OAAI

An MRI radiomics approach to predict survival and tumour-infiltrating macrophages in gliomas

BRAIN

IF11.7

2022-02-06136

OAAI

The impact of rifampicin on the pharmacokinetics of fuzuloparib in healthy Chinese male volunteers

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

IF3

2021-12-267

OAAI

Galectin-9/TIM-3 as a Key Regulator of Immune Response in Gliomas With Chromosome 1p/19q Codeletion

FRONTIERS IN IMMUNOLOGY

IF5.9

2021-12-087

OAAI

NK Cell-Based Immunotherapy and Therapeutic Perspective in Gliomas

FRONTIERS IN ONCOLOGY

IF3.3

2021-10-2618

OAAI

Pharmacokinetics, Safety, and Tolerability of Ravidasvir, with and without Danoprevir/Ritonavir, in Healthy Subjects

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2021-09-172

Metabolic expression profiling stratifies diffuse lower-grade glioma into three distinct tumour subtypes

BRITISH JOURNAL OF CANCER

IF6.8

2021-05-1812

OAAI

You Zhai

个人简介

教育背景

工作经历

荣誉奖项

研究方向